Zenith Laboratories Inc said thecompany will report a fourth quarter loss, and the amount willbe determined on completion of its year end audit. The companydid not elaborate further.    For the third quarter ended Sept 30, 1986, Zenith reporteda loss of 3,451,000 dlrs or 16 cts per share, adjusted for aMay 1986 2-for-1 stock split.    The company also said it received Food and DrugAdministration approval to market Cefadroxil, a generic versionof an antibiotic with domestic sales exceeding 50 mln dlrs in1986.    Zenith said it will not market the drug until "questionsrelating to the applicability of certain patents have beenresolved." Reuter&#3;